Head-To-Head Review: Autonomix Medical (NASDAQ:AMIX) versus Lucid Diagnostics (NASDAQ:LUCD)

Lucid Diagnostics (NASDAQ:LUCDGet Free Report) and Autonomix Medical (NASDAQ:AMIXGet Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, institutional ownership, analyst recommendations and profitability.

Profitability

This table compares Lucid Diagnostics and Autonomix Medical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Lucid Diagnostics -1,227.74% N/A -112.67%
Autonomix Medical N/A N/A N/A

Insider & Institutional Ownership

74.0% of Lucid Diagnostics shares are owned by institutional investors. Comparatively, 10.8% of Autonomix Medical shares are owned by institutional investors. 8.8% of Lucid Diagnostics shares are owned by insiders. Comparatively, 32.4% of Autonomix Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Lucid Diagnostics and Autonomix Medical”s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Lucid Diagnostics $3.80 million 10.81 -$52.67 million ($1.27) -0.62
Autonomix Medical N/A N/A -$15.43 million N/A N/A

Autonomix Medical has lower revenue, but higher earnings than Lucid Diagnostics.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Lucid Diagnostics and Autonomix Medical, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lucid Diagnostics 0 0 4 1 3.20
Autonomix Medical 0 0 1 0 3.00

Lucid Diagnostics presently has a consensus target price of $3.94, indicating a potential upside of 402.62%. Autonomix Medical has a consensus target price of $1.40, indicating a potential upside of 136.89%. Given Lucid Diagnostics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Lucid Diagnostics is more favorable than Autonomix Medical.

Summary

Lucid Diagnostics beats Autonomix Medical on 6 of the 10 factors compared between the two stocks.

About Lucid Diagnostics

(Get Free Report)

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

About Autonomix Medical

(Get Free Report)

Autonomix Medical, Inc., a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.

Receive News & Ratings for Lucid Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lucid Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.